Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Accelerating Medicines Partnership® Schizophrenia Observational Study: Psychosis Risk Evaluation, Data Integration, and Computational Technologies -Data Processing, Analysis, and Coordination Center and Coordination Center

NCT05905003 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT05905003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05905003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Accelerating Medicines Partnership® Schizophrenia Observational Study: Psychosis Risk Evaluation, Data Integration, and Computational Technologies -Data Processing, Analysis, and Coordination Center and Coordination Center
Lead sponsor
Brigham and Women's Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
June 2, 2022
Completion date
April 30, 2027
Enrollment
2,617 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

clinical high risk, conversion, psychosis, remission